SCHEMBL3218306

SCHEMBL3218306

CC(=O)c1ccc(O)c(O)c1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SELL P14151 1/20 0.45
SELP P16109 1/20 0.45
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 2/20 0.44
MAPK1 P28482 2/20 0.44
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALOX15 P16050 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PIK3CA P42336 3/20 0.42
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
POLB P06746 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP3A4 P08684 1/20 0.41
NSD2 O96028 1/20 0.41
MCL1 Q07820 1/20 0.41
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31346680 1.00 SELL (0.45) SELLSELPALDH1A1MAPTHPGD
SCHEMBL6247069 0.84 MAPK1 (0.46) SELLSELPALDH1A1MAPTHPGD
SCHEMBL15680145 0.83 SELL (0.42) SELLSELPALDH1A1MAPTHPGD
SCHEMBL4509639 0.83 DPP4 (0.43) ALDH1A1MAPTHPGDMAPK1GAA
SCHEMBL481034 0.83 MAPT (0.44) SELLSELPALDH1A1MAPTHPGD
SCHEMBL28842145 0.82 SELL (0.48) SELLSELPALDH1A1MAPTHPGD
SCHEMBL6243876 0.81 MAPT (0.43) SELLSELPALDH1A1MAPTHPGD
SCHEMBL15680449 0.80 SELL (0.39) SELLSELPALDH1A1MAPTHPGD
SCHEMBL3546145 0.80 SELL (0.64) SELLSELPALDH1A1MAPTHPGD
Gallacetophenone SCHEMBL105704 0.79 SELL (0.62) SELLSELPALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115611750-B Method for synthesizing isoprenaline hydrochloride 成都新恒创药业有限公司 2024-07-09 CN claimed
CN-115611750-A Synthesis method of isoproterenol hydrochloride 成都新恒创药业有限公司 2023-01-17 CN claimed
CN-108927143-B Preparation method of pharmaceutical intermediate for treating open-angle glaucoma 北京宝诺康医药科技有限公司 2020-01-03 CN claimed
CN-110590517-A Preparation method of 3, 4-dihydroxy-2' -chloroacetophenone 武汉嘉诺康医药技术有限公司 2019-12-20 CN claimed
CN-108927143-A A kind of preparation method for treating open-angle glaucoma pharmaceutical intermediate 王淑英 2018-12-04 CN claimed
EP-4734929-A1 SYSTEM AND METHODS FOR MODIFYING SURFACE PROPERTIES OF KERATIN-CONTAINING SURFACES Edulis Labs Inc. (US) 2026-05-06 EP disclosed
US-20250143307-A1 GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF DEBOGY MOLECULAR, INC. (US) 2025-05-08 US disclosed
US-20250000091-A1 GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF DEBOGY MOLECULAR, INC. (US) 2025-01-02 US disclosed
WO-2025006080-A1 SYSTEM AND METHODS FOR MODIFYING SURFACE PROPERTIES OF KERATIN-CONTAINING SURFACES EDULIS LABS INC. (US) 2025-01-02 WO disclosed
CN-115611750-B Method for synthesizing isoprenaline hydrochloride 成都新恒创药业有限公司 2024-07-09 CN disclosed
CN-115611750-B Method for synthesizing isoprenaline hydrochloride 成都新恒创药业有限公司 2024-07-09 CN disclosed
CN-112694608-B Six-arm polyethylene glycol derivative, preparation method and modified biological related substance 厦门赛诺邦格生物科技股份有限公司 2024-07-02 CN disclosed
US-6241785-B1 HOIR DYES L'OREAL (FR) 2001-06-05 US disclosed
EP-0949897-B1 USE OF FLAVYLIUM TYPE COMPOUNDS NON-SUBSTITUTED IN POSITION 3 FOR DYEING KERATINOUS FIBRES AND COMPOSITIONS CONTAINING THEM OREAL (FR) 2001-05-23 EP disclosed
EP-0949897-A1 USE OF FLAVYLIUM TYPE COMPOUNDS NON-SUBSTITUTED IN POSITION 3 FOR DYEING KERATINOUS FIBRES AND COMPOSITIONS CONTAINING THEM L'OREAL (FR) 1999-10-20 EP disclosed
WO-1998027940-A1 USE OF FLAVYLIUM TYPE COMPOUNDS NON-SUBSTITUTED IN POSITION 3 FOR DYEING KERATINOUS FIBRES AND COMPOSITIONS CONTAINING THEM L'OREAL (FR) 1998-07-02 WO disclosed
EP-0638075-A1 THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-02-15 EP disclosed
WO-1994019335-A1 THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-09-01 WO disclosed
US-4470997-A Esters IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-09-11 US disclosed
US-4423070-A DI- AND TRIESTERS OF N-(ACYLAMINOALKYL)-DIHYDROXYPHENYLETHANOLAMINES, ANTIINFLAMMATORY IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1983-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250143307-A1 GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF BSG, PBK, ALG1 SELL 1581/4885SELP 1935/4885ALDH1A1 1906/4885
US-20250000091-A1 GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF ALG1, BSG, BTD SELL 1225/4885SELP 1552/4885ALDH1A1 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.